Favipiravir is an antiviral drug that has been shown to treat a variety of life-threatening infections, including Ebola, Lassa, and the COVID-19 virus. It's a pyrazine carboxamide derivative with antiviral action that targets RNA-dependent RNA polymerase enzymes, which are required for viral genome transcription and replication. Favipiravir is an antiviral previously indicated for influenza and Ebola, which has shown some promise in early trials for treatment of COVID-19. The nucleoside analogue favipiravir is rapidly metabolized in host cells which disrupts viral synthesis and leads to mutagenesis The mechanism of action of the Favipiravir and Side effects like QTc prolongation or teratogenicity pose risk to extensive community application discusses in this review. In this article, we have tried to provide a comprehensive, evidence-based review of this drug about synthesis, Pharmacology, Mechanism of Action, Antiviral activity, Consequences.
Cite this article:
Ganesh Bharskar, Pratik Malvade. Favipiravir: An Antiviral Drug. Research Journal of Science and Technology. 2022; 14(4):253-0. doi: 10.52711/2349-2988.2022.00041
Ganesh Bharskar, Pratik Malvade. Favipiravir: An Antiviral Drug. Research Journal of Science and Technology. 2022; 14(4):253-0. doi: 10.52711/2349-2988.2022.00041 Available on: https://rjstonline.com/AbstractView.aspx?PID=2022-14-4-9
1. National Center for Biotechnology Information. PubChem Compound Summary for CID 492405, Favipiravir. https://pubchem.ncbi.nlm.nih.gov/compound/Favipiravir. Accessed June 3, 2022
2. Acquavia MA, Foti L, Pascale R, Nicolò A, Brancaleone V, Cataldi TRI, Martelli G, Scrano L, Bianco G. Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. Talanta. 2021 March 1;224.
3. China patent (CN104914185A). HPLC method for measuring related substances in favipiravir.
4. Smee Donald F, Hurst Brett L, Egawa Hiroyuki, Takahashi Kazumi, Kadota Takumi, Furuta Yousuke. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother. 2009;64(4):741-6.
5. T. Tanaka, T. Kamiyama, et al., T-705 (Favipiravir) suppresses tumor necrosis factor a production in response to influenza virus infection: a beneficial feature of T-705 as an anti-influenza drug, Acta Virol. (2017); 61(1); 48-55.
6. C.-Q. Bai, J.-S. Mu, et al., Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)—Sierra Leone, Clin. Infect. Dis. 63(10) (2016) 1288–1294,
7. A.A. Elfiky, SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective, J. Biomol. Struct. Dyn. (2020) 1–9,
8. N. Zhu, D. Zhang, et al., A novel coronavirus from patients with pneumonia in China- 2019, New Eng. J. Med. (2020),
9. S.C. Ferreira, R. Bruns, et al., Box-Behnken design: an alternative for the optimization of analytical methods, Anal. Chim. Acta 597 (2007) 179–186,
10. Guo Q, Xu M, Guo S, Zhu F, Xie Y, Shen J. Chem. Pap. 2019;73:1043.
11. Liu F-L, Li C-Q, Xiang H-Y, Feng S. Chem. Pap. 2017;71:2153.
12. Furuta Y., Gowen B.B., Takahashi K., Shiraki K., Smee D.F., Barnard D.L. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013 Nov;100:446–454
13. Toyama Chemicals. Summary of Product Characteristics of Avigan.
14. Madelain V., Nguyen T.H., Olivo A. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin Pharmacokinet. 2016 Aug;55:907–923.
15. Madelain, V. et al. Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials. Clin. Pharmacokinet. 55; (2016); 907– 923
16. Mentre, F. et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect. Dis. 15, (2015);150– 151.
17. Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Report on the Deliberation Results [Internet] <https://www.pmda.go.jp/files/000210319.pdf> (2014).
18. Bocan, T.M. et al. Synthesis of [(18)F]Favipiravir and biodistribution in C3H/HeN mice as assessed by positron emission tomography. Sci. Rep. 9, (2019);1785
19. Madelain, V. et al. Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses. Antimicrob. Agents Chemother. 61, (2017); 1305– 1316.
20. Nguyen, T.H. et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis. 11, (2017); 5389.
21. Jin Z., Smith L.K., Rajwanshi V.K., Kim B., Deval J. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase.;2013.
22. Baranovich T., Wong S.S., Armstrong J. 705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol. 87;2013; 3741–3751
23. Wang, D.C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA.
24. Guan, W.C. et al. Clinical characteristics of 2019 novel coronavirus infection in China. N. Engl. J. Med. 382; 2020;1708-1720
25. Zhao, Y. et al. Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. Br. J. Clin. Pharmacol. 80, (2015); 1076– 1085
26. Sleeman K., Mishin V.P., Deyde V.M., Furuta Y., Klimov A.I., Gubareva L.V. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother. 54:2010; 2517–2524.
27. Oestereich L., Lüdtke A., Wurr S., Rieger T., Muñoz-Fontela C., Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res. 105;2014; 17–21
28. Kerber R., Lorenz E., Duraffour S. Laboratory findings, compassionate use of favipiravir, and outcome in patients with ebola virus disease, Guinea, 2015-A retrospective observational study. J Infect Dis. 220; 2019; 195–202
29. Pharmaceuticals and Medical Devices Agency. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau; 2011. Report on the Deliberation Results – Avigan. Japan.
30. Kumagai Y., Murakawa Y., Hasunuma T. Lack of effect of favipiravir, a novel antiviral agent, on the QT interval in healthy Japanese adults. Int J Clin Pharm Ther. 53;2015; 866–674.
31. Pilkington V., Pepperrell T., Hill A. A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic J?. Virus Erad. 6;2020; 45–51
32. Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report
33. Erdem, H. et al. Treatment of SARS-cov-2 pneumonia with Favipiravir: Early results from the Ege University cohort, Turkey. Turk. J. Med. Sci. (2020).
34. Pérez-García, A. et al. A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc an d/or Favipiravir vs Currently Used Therapy in Severe COVID- 19 Adults.“COMVIVIR” Trial. (2020).
35. Dabbous, H. M., El-Sayed, M. H., El Assal, G., Elghazaly, H., Ebeid, F. F., Sherief, A.F. et al. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. Sci. Rep. 11, 1–7 (2021).
36. Dwadia, Z. F. et al. Efficacy and safety of Favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int. J. Infect. Dis. (IJID) 103, 2020;62– 71.
37. Shrestha, D. B. et al. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: A rapid systematic review and meta-analysis. Virol J. 17; 2020; 141– 141.
38. Prajapat Manisha, Sarma Phulen, Shekhar Nishant, Avti Pramod, Sinha Shweta, Kaur Hardeep, Kumar Subodh, Bhattacharyya Anusuya, Kumar Harish, Bansal Seema,Medhi Bikash. Drug targets for coronavirus: A systematic review. Indian J Pharmacol. 52(1):2020; 56- 65.
39. Noda, A., Shirai, T., Nakajima, H. Case Report Two Cases of COVID-19 Pneumonia Including Use of Favipiravir. 1–6. Available at: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_en_200408_2.pdf. (2021). Accessed 3 Jun 2022.